Literature DB >> 21119717

Comorbidities: glucocorticoids and osteoporosis: predicting fracture risk.

Stanley B Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21119717     DOI： 10.1038/nrrheum.2010.194

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  The appropriateness method.

Authors:  Paul Shekelle
Journal:  Med Decis Making       Date:  2004 Mar-Apr       Impact factor: 2.583

Review 2.  American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Jennifer M Grossman; Rebecca Gordon; Veena K Ranganath; Chad Deal; Liron Caplan; Weiling Chen; Jeffrey R Curtis; Daniel E Furst; Maureen McMahon; Nivedita M Patkar; Elizabeth Volkmann; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07-26       Impact factor: 4.794

Review 3.  FRAX and its applications to clinical practice.

Authors:  John A Kanis; Anders Oden; Helena Johansson; Fredrik Borgström; Oskar Ström; Eugene McCloskey
Journal:  Bone       Date:  2009-02-03       Impact factor: 4.398

4.  A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids.

Authors:  T-P van Staa; P Geusens; H A P Pols; C de Laet; H G M Leufkens; C Cooper
Journal:  QJM       Date:  2005-03

Review 5.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

Authors: 
Journal:  Arthritis Rheum       Date:  2001-07

6.  Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.

Authors:  Jeffrey R Curtis; Andrew O Westfall; Jeroan J Allison; Angela Becker; Linda Casebeer; Allison Freeman; Claire M Spettell; Norman W Weissman; Scott Wilke; Kenneth G Saag
Journal:  Arthritis Rheum       Date:  2005-08

7.  Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Authors:  Kenneth G Saag; Elizabeth Shane; Steven Boonen; Fernando Marín; David W Donley; Kathleen A Taylor; Gail P Dalsky; Robert Marcus
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

8.  Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

Authors:  David M Reid; Jean-Pierre Devogelaer; Kenneth Saag; Christian Roux; Chak-Sing Lau; Jean-Yves Reginster; Philemon Papanastasiou; Alberto Ferreira; Florian Hartl; Taiwo Fashola; Peter Mesenbrink; Philip N Sambrook
Journal:  Lancet       Date:  2009-04-11       Impact factor: 79.321

9.  Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.

Authors:  T P Van Staa; R F Laan; I P Barton; S Cohen; D M Reid; C Cooper
Journal:  Arthritis Rheum       Date:  2003-11
  9 in total
  1 in total

1.  Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients.

Authors:  Mohammad Keilani; Christoph Krall; Christine Marosi; Birgit Flechl; Karin Dieckmann; Georg Widhalm; Maximilian Marhold; Richard Crevenna
Journal:  Wien Klin Wochenschr       Date:  2012-06-12       Impact factor: 1.704
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.